Repurposing of FDA Approved Drugs as COVID-19 Therapeutics: Safety Concerns and Contraindications of Drugs in Clinical Trials

Ravinder Naik Dharavath; Meenu Dutt; Sunil Kumar; Priya Badyal; Nitin Rawat; Tanzeer Kaur; Shweta Sharma; Mahendra Bishnoi; Kanwaljit Chopra

doi:10.20944/preprints202006.0232.v1

Preprint Review Version 1 This version is not peer-reviewed

Repurposing of FDA Approved Drugs as COVID-19 Therapeutics: Safety Concerns and Contraindications of Drugs in Clinical Trials

Ravinder Naik Dharavath ^* ,

Meenu Dutt ,

Sunil Kumar ,

Nitin Rawat ,

Version 1 : Received: 16 June 2020 / Approved: 18 June 2020 / Online: 18 June 2020 (12:43:43 CEST)

How to cite: Dharavath, R.N.; Dutt, M.; Kumar, S.; Badyal, P.; Rawat, N.; Kaur, T.; Sharma, S.; Bishnoi, M.; Chopra, K. Repurposing of FDA Approved Drugs as COVID-19 Therapeutics: Safety Concerns and Contraindications of Drugs in Clinical Trials. Preprints 2020, 2020060232 (doi: 10.20944/preprints202006.0232.v1). Dharavath, R.N.; Dutt, M.; Kumar, S.; Badyal, P.; Rawat, N.; Kaur, T.; Sharma, S.; Bishnoi, M.; Chopra, K. Repurposing of FDA Approved Drugs as COVID-19 Therapeutics: Safety Concerns and Contraindications of Drugs in Clinical Trials. Preprints 2020, 2020060232 (doi: 10.20944/preprints202006.0232.v1).

Abstract

Coronavirus disease (COVID-19) is the current global public health threat with no specific, effective, and approved treatment available till date. The outbreak of COVID-19 has led the world into an unimagined and uncertain situation by disrupting the economies, claiming human lives, and leaving many into secondary mental health problems. As per the latest WHO report, approximately 8.2 million people are infected, and nearly 0.44 million lives are lost to COVID. The infection has spread to over 200 countries and territories around the world. The world is in search of efficient diagnostics and therapeutics, including vaccines, biologics and drugs. With the rapid increase in rates of infection and time constraints, drug repurposing seems to be a potential and viable option to find the promising anti-COVID therapeutics. In the wake of a rapid increase in the number of clinical trials involving drugs for repurposing, we aim to provide information on the safety concerns related to the drugs currently investigated in trials. This review also highlights the possible mechanisms of actions, adverse drug reactions, and contraindications of the drugs under repurposing evaluation.

Subject Areas

Adverse drug reactions; Anti-COVID drugs; Coronavirus; Drug repurposing; Drug toxicity; Pharmacotherapy

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (1)

Comment 1

Received: 18 June 2020
Commenter: Ritu Sharma
The commenter has declared there is no conflict of interests.

Comment: Productive information and gives a broad outlook to the crisis going on now.

+ Respond to this comment

Your full name

Your affiliation information (e.g., name of your university/institution/organization)

Not displayed online.

Your Email address (not made public)

Please leave your comment to this article below.

Mathematical equations can be typed in either LaTeX formats \\[ ... \\] or $$ ... $$, or MathML format <math> ... </math>. Try the LaTeX or MathML example.

Type equation:

Preview:

Copy equation into message below

Close menu

Please click a symbol to insert it into the message box below:

Please enter the link here:

Optionally, you can enter text that should appear as linked text:

Copy link into message below

Close menu

Please enter or paste the URL to the image here (please only use links to jpg/jpeg, png and gif images):

Copy image into message below

Close menu

Type author name or keywords to filter the list of references in this group (you can add a new citation under Bibliography):

No existing citations in Discussion Group

Wikify editor is a simple editor for wiki-style mark-up. It was written by MDPI for Sciforum in 2014. The rendering of the mark-up is based on Wiky.php with some tweaks. Rendering of mathematical equations is done with MathJax. Please send us a message for support or for reporting bugs.

Close menu

Please declare any conflicts of interest you may have with this paper, financial or otherwise.

I do not have a conflict of interest

I would like to declare a conflict of interest

Display my name on the website I want to get recognition for my comment on Publons

[what’s this?]. Link your accounts here

Captcha

Renew

I accept the following conditions:

Comments must follow the standards of professional discourse and should focus on the scientific content of the article. Insulting or offensive language, personal attacks and off-topic remarks will not be permitted. Comments must be written in English. Preprints reserves the right to remove comments without notice. Readers who post comments are obliged to declare any competing interests, financial or otherwise.

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)

Get PDF Cite Share

Bookmark BibSonomy Mendeley Reddit Delicious Publons

Alerts

Notify me about updates to this article or when a peer-reviewed version is published.